Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total value of $250,458.36. Following the completion of the transaction, the chief operating officer now directly owns 67,109 shares in the company, valued at approximately $7,391,385.26. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.91, for a total value of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total value of $216,257.40.

Blueprint Medicines Stock Up 4.1 %

NASDAQ:BPMC opened at $115.63 on Friday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a market cap of $7.35 billion, a PE ratio of -54.80 and a beta of 0.61. The company’s 50 day moving average is $95.28 and its two-hundred day moving average is $95.48.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the firm earned ($2.20) EPS. The firm’s revenue was up 126.5% on a year-over-year basis. Analysts anticipate that Blueprint Medicines Co. will post -3.67 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Amalgamated Bank increased its holdings in Blueprint Medicines by 5.3% in the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock worth $232,000 after buying an additional 109 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Blueprint Medicines by 12.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,276 shares of the biotechnology company’s stock valued at $461,000 after acquiring an additional 485 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Blueprint Medicines in the second quarter worth $1,060,000. Sei Investments Co. raised its holdings in shares of Blueprint Medicines by 15.4% during the second quarter. Sei Investments Co. now owns 52,986 shares of the biotechnology company’s stock worth $5,711,000 after purchasing an additional 7,073 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in Blueprint Medicines during the second quarter valued at $7,458,000.

Wall Street Analyst Weigh In

A number of research firms have commented on BPMC. Wedbush reissued an “outperform” rating and set a $124.00 target price (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. UBS Group began coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, January 15th. JPMorgan Chase & Co. began coverage on Blueprint Medicines in a research report on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price on the stock. Finally, StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $122.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.